Literature DB >> 20560289

Fatigue in sarcoidosis: American versus Dutch patients.

W P E de Kleijn1, M D P Elfferich, J De Vries, G J Jonker, E E Lower, R P Baughman, T E King, M Drent.   

Abstract

BACKGROUND: Fatigue is a major problem in sarcoidosis. Fatigue has mainly been examined in patients from The Netherlands.
OBJECTIVE: The aims of the study were to establish the prevalence of fatigue in US and Dutch patients and to determine whether fatigue was related to the common demographic and clinical parameters.
DESIGN: Two patients groups were studied: Dutch outpatients at Maastricht University Medical Center in The Netherlands (n = 121) and US patients at the University of Cincinnati Medical Center in the USA (n = 126). Both groups completed the Fatigue Assessment Scale. Clinical data were gathered from the patients' medical files.
RESULTS: The prevalence of fatigue was similar in the US and Dutch patients, but more severe in the latter group. Fatigue was unrelated to demographic and clinical parameters in the total group. However, when examining the US and Dutch patients separately, fatigue was associated with age, extrapulmonary involvement and drug use in the US group.
CONCLUSIONS: Dutch patients report more severe fatigue compared with US patients. Interestingly, fatigue was related to clinical and demographical parameters in the US patients, although no such relationships was found in the Dutch patients.

Entities:  

Mesh:

Year:  2009        PMID: 20560289

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  14 in total

Review 1.  A concise review of pulmonary sarcoidosis.

Authors:  Robert P Baughman; Daniel A Culver; Marc A Judson
Journal:  Am J Respir Crit Care Med       Date:  2010-10-29       Impact factor: 21.405

Review 2.  Disease Burden and Variability in Sarcoidosis.

Authors:  Alicia K Gerke; Marc A Judson; Yvette C Cozier; Daniel A Culver; Laura L Koth
Journal:  Ann Am Thorac Soc       Date:  2017-12

Review 3.  Patient reported outcome measures (PROMs) in sarcoidosis.

Authors:  Rikke Flor Thunold; Anders Løkke; Adam Langballe Cohen; Hilberg Ole; Elisabeth Bendstrup
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

4.  The indications for the treatment of sarcoidosis: Wells Law.

Authors:  Robert P Baughman; Marc A Judson; Athol Wells
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

5.  Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial.

Authors:  Elyse E Lower; Atul Malhotra; Victoria Surdulescu; Robert P Baughman
Journal:  J Pain Symptom Manage       Date:  2012-08-20       Impact factor: 3.612

6.  Exercise capacity, muscle strength, and fatigue in sarcoidosis: a follow-up study.

Authors:  Rik G J Marcellis; Antoine F Lenssen; Stephan Kleynen; Jolanda De Vries; Marjolein Drent
Journal:  Lung       Date:  2013-04-05       Impact factor: 2.584

7.  Presence of onconeural antibodies in sarcoidosis patients with parasarcoidosis syndrome.

Authors:  Elyse E Lower; Madison Sturdivant; Robert P Baughman
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

8.  A predictive tool for an effective use of (18)F-FDG PET in assessing activity of sarcoidosis.

Authors:  Rémy L M Mostard; Sander M J Van Kuijk; Johny A Verschakelen; Marinus J P G van Kroonenburgh; Patty J Nelemans; Petal A H M Wijnen; Marjolein Drent
Journal:  BMC Pulm Med       Date:  2012-09-14       Impact factor: 3.317

9.  Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis.

Authors:  R J Erckens; R L M Mostard; P A H M Wijnen; J S Schouten; M Drent
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-11-27       Impact factor: 3.117

Review 10.  Managing fatigue in sarcoidosis - A systematic review of the evidence.

Authors:  Chris Atkins; Andrew M Wilson
Journal:  Chron Respir Dis       Date:  2016-08-09       Impact factor: 2.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.